anti-cd20 monoclonal antibody

Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody that displays anti-proliferative, apoptotic, and antibody-dependent cytotoxic effects in vitro and inhibits tumor growth in mice harboring human lymphomas, and is indicated for use in non-Hodgkin's lymphoma (NHL).

Ocaratuzumab (AME 133v), an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, demonstrates enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) [1] [2] with a dissociation constant (Kd) of approximately 100 pM.

Ibritumomab is a murine-derived anti-CD20 monoclonal antibody that kills tumor cells by forming free radicals in target cells and surrounding tissues.Ibritumomab is used in the study of non-Hodgkin's lymphoma.

The Anti-Mouse CD20 Antibody (MB20-11) is a mouse monoclonal IgG2c kappa antibody designed for in vivo use, specifically targeting CD20. The recommended isotype control for this antibody is Mouse IgG2c kappa, Isotype Control.

BI-1206 is a recombinant antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). It inhibits CD20 internalization induced by Rituximab, whether used alone or in combination with drugs such as Ibrutinib, Venetoclax, and CHOP. BI-1206 can enhance or restore the activity of Rituximab or other anti-CD20 monoclonal antibodies and demonstrates cytolytic activity against malignant B cells. BI-1206 is applicable in research on cancers such as mantle cell lymphoma (MCL).